Lilly says Foundayo cuts predicted 10-year type 2 diabetes risk 57% in ATTAIN-1 post-hoc analysis

Bitget2026/10/01 11:04

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Eli Lilly disclosed post-hoc analyses from its Phase 3 ATTAIN-1 trial; findings were published in Diabetes, Obesity and Metabolism.
The modeling linked once-daily oral obesity drug Foundayo to lower predicted long-term risk of type 2 diabetes versus placebo.
The highest dose also pointed to a reduced predicted long-term cardiovascular disease risk, supporting a broader cardiometabolic value proposition.
Results add to the commercial case for Foundayo in chronic weight management, where payers are weighing long-term cost offsets from risk reduction.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eli Lilly and Company published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610010700PR_NEWS_USPR_____DE57577) on October 01, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Lilly says Foundayo cuts predicted 10-year type 2 diabetes risk 57% in ATTAIN-1 post-hoc analysis

You may also like

Crypto prices